## Introduction to meta-analysis in Review Manager (RevMan). 5.2

Xiaojin Yu



### **Session overview**

- Open Revman
- Adding studies
- Add comparison
- □ Add outcome
- Data entry
- Conducting meta-analysis
- Generating plots and graphs

# **Review Manager (RevMan)**

- A software FROM The Cochrane Collaboration for preparing and maintaining Cochrane reviews.
- RevMan facilitates preparation of protocols and full reviews
- □ It is most useful when you have formulated the question for the review and allows you to:
  - prepare the text,
  - build the tables showing the characteristics of studies and the comparisons in the review,
  - add study data,
  - perform meta-analyses and
  - present the results graphically.

Download here: <u>http://ims.cochrane.org/revman/download</u>

#### **Categorical data Example**

| atudica     |          | ASprin   |          | placebo  |  |  |
|-------------|----------|----------|----------|----------|--|--|
| studies     | death(n) | total(N) | death(n) | total(N) |  |  |
| MRC-1 1974  | 49       | 615      | 67       | 624      |  |  |
| CDP 1976    | 44       | 758      | 64       | 771      |  |  |
| MRC-2 1979  | 102      | 832      | 126      | 850      |  |  |
| GASP 1979   | 32       | 317      | 38       | 309      |  |  |
| PARIS 1980  | 85       | 810      | 52       | 406      |  |  |
| AMIS 1980   | 246      | 2267     | 219      | 2257     |  |  |
| ISIS-2 1988 | 1570     | 8587     | 1720     | 8600     |  |  |

## **RevMan5.2 tour**

Building your review or protocol
Add studies
Assess studies
Data input

| 5 Welcome to Review Manager 5.2  |   |
|--|---|
| What do you like to do?   Image: Open a review from a file   Image: Open a review from a file   Image: Open a review   Image: Open a review <td< th=""><th>Place your mouse cursor over an option to learn<br/>more about it.</th></td<> | Place your mouse cursor over an option to learn<br>more about it. |
| On startup, show: Welcome screen   | ▼ <u>C</u> lose   |

#### Welcome page

| 5 Review Manager 5                                      |                                    |  |        |
|---|------------------------------------|--|--------|
| <u>File E</u> dit F <u>o</u> rmat <u>V</u> iew <u>I</u> | ools T <u>a</u> ble <u>W</u> indow | <u>H</u> elp   |        |
|   |                                    |  |        |
|   |                                    |  |        |
|   |                                    |  |        |
|   |                                    |  |        |
| l r   | 🗟 Now Review Mizard                |  |        |
|   |                                    |  |        |
|   | New Review Wizard                  |  | ?      |
|   | weicome                            |  |        |
|   | Walaamat                           | o the New Review Wizerd  |        |
|   | welcome t                          |  |        |
|   | This wizard helps y                | u create a new review for other purposes than publication in The Cochrane Library. |        |
|   | If you want to create              | a Cochrane review for publication, please contact the appropriate Review Group.    |        |
|   |                                    |  |        |
|   |                                    |  |        |
|   | To continue, click N               | ext.   |        |
|   |                                    |  |        |
|   | Cancel                             | < Back Novt >  | Einich |
|   | Gancer                             |  |        |
|   |                                    |  |        |
|   |                                    |  |        |
|   |                                    |  |        |
|   |                                    |  |        |

#### Types of review

| Review Wizard                               | ×              |
|---|----------------|
| New Review Wizard                           | ? 间            |
| Which type of review do you want to create? |                |
| Intervention review                         |                |
|   |                |
|   |                |
| Methodology review                          |                |
| Overview of reviews                         |                |
|   |                |
|   |                |
|   |                |
| <u>Cancel</u> < <u>B</u> ack <u>N</u> ext > | <u>F</u> inish |

## **Title of your SR**

| 👩 Ne       | w Review Wizard                 |            |                          |                |                               |     |                              |
|------------|---------------------------------|------------|--------------------------|----------------|-------------------------------|-----|------------------------------|
| New        | Review Wizard                   |            |                          |                |                               | 2   | 0                            |
|            | hat is the title of the review? |            |                          |                |                               |     |                              |
| Title:     |                                 |            |                          |                |                               |     |                              |
| ۲          | [Intervention]                  | <b>Ø</b> N | ew Review Wizard         |                |                               |     | X                            |
| 0          | [Intervention A]                | New        | Review Wizard            | v?             |                               |     | ?                            |
| $\circ$    | [Intervention]                  | Title      |                          |                |                               |     |                              |
| 0          | [Use if title does not fit a    | Inte       |                          |                |                               |     |                              |
|            | 1                               |            | asprin                   | for            | myocardial infarction         |     |                              |
|            |                                 | 0          | [Intervention A]         | versus         | [intervention B]              | for | [health problem]             |
|            |                                 | 0          | [Intervention]           | for            | [health problem]              | in  | [participant group/location] |
| <u>C</u> á | ancel                           | $\circ$    | [Use if title does not f | fit any of the | formats above]                |     |                              |
|            |                                 |            |                          |                |                               |     |                              |
|            |                                 |            |                          |                |                               |     |                              |
|            |                                 |            |                          |                |                               |     |                              |
|            |                                 |            | ancel                    |                | < <u>B</u> ack <u>N</u> ext > | •   | <u>F</u> inish               |

## **Protocol or Full review**

| Review Wizard  |                              | X              |
|--|------------------------------|----------------|
| New Review Wizard<br>Which stage should the review start in? |                              | ?              |
| Stage:   |                              |                |
| ○ <u>T</u> itle only   |                              |                |
| ○ Protocol   |                              |                |
| Eull review  |                              |                |
|  |                              |                |
|  |                              |                |
|  |                              |                |
|  |                              |                |
| <u>C</u> ancel   | < <u>Back</u> <u>N</u> ext > | <u>F</u> inish |

### There you are



#### Add Studies & references



- □ ① "Studies and references" "References to studies";
- 2 "References to studies" "Included studies";
- □ ③ "Add Study"\_ "New Study Wizard"
- □ ④ "New Study Wizard", "Study ID"





## Add outcome

MortalityBlood pressure

| 💐 New Outcom                 | e Wizard                          |                |
|------------------------------|-----------------------------------|----------------|
| New Outcome V<br>What name s | Vizard<br>hould the outcome have? | ?              |
| <u>N</u> ame:                |                                   |                |
| Group Label 1:               | Experimental                      |                |
| Group <u>L</u> abel 2:       | Control                           |                |
|                              |                                   |                |
|                              |                                   |                |
|                              |                                   |                |
|                              |                                   |                |
|                              |                                   |                |
| <u>C</u> ancel               | < <u>B</u> ack <u>N</u> ext>      | <u>F</u> inish |

#### **Data & analyses**

"Data and Analysis" add new comparison Outcome Wizard" "Dichotomous"

| 🚽 New Outcome Wizard                                |   | X   |
|---|---|---|
| New Outcome Wizard<br>What type of outcome do you w | 💐 New Outcome Wizard                              |   |
| Data Type:  | New Outcome Wizard<br>What type of outcome do you | want to create?                             |
| ⊖ <u>C</u> ontinuous                                | Data Type:  | Description:                                |
| O-E and Variance                                    | ○ <u>D</u> ichotomous                             | experimental and control groups.            |
| ○ <u>G</u> eneric Inverse Variance                  | <u>C</u> ontinuous                                |   |
| ○ O <u>t</u> her Data                               | <u>O</u> -E and variance <u>O</u> -E and variance |   |
|   | Other Data  |   |
|   |   |   |
|   |   |   |
| Cancel  |   |   |
|   | Cancel  | < <u>Back</u> <u>Next&gt;</u> <u>Finish</u> |

#### Add data

Text of Review X 1.1 m

¢

X 1.1 mortality

#### Comparison: 1 a vs b, Outcome: 1.1 mortality

| Study or Subgroup            |                  | Experi  | mental | Cor    | ntrol       | Woight       | Odd         |
|------------------------------|------------------|---|--------|--------|-------------|--------------|-------------|
|                              |                  | Events  | Total  | Events | Total       | weight       | M-H, Fi     |
| Total (95% CI)               |                  |   | 0      |        | 0           |              | N           |
| Total events                 |                  | 0   |        | 0      |             |              |             |
| Heterogeneity: Not applic    | ahla             | - · ·   |        |        |             |              |             |
| Test for overall effect: Not | applica          |   |        |        |             |              |             |
|                              |                  |   |        |        |             |              |             |
| New Study Data Wiz           | ard See          |   |        |        |             |              |             |
| New Study Data Wizar         | d                |   |        |        |             |              |             |
| Which studies do yo          | u want to a      | add data f  | for?   |        |             |              |             |
| Included Studies:            |                  |   |        |        |             |              |             |
|                              |                  | ilter by  |        |        |             |              |             |
| a2007                        | [                | ilter by:—<br>(ear rang                                   | 0.     | t      |             | _            |             |
| a2007                        | F                | ilter by:<br>/ear rang                                    | e:     | t      | D           |              |             |
| a2007<br>b2001<br>c2008      | F<br>Y           | ilter by:<br>/ear rang<br>Dutcome                         | e:     | t      | D           |              |             |
| a2007<br>b2001<br>c2008      | F<br>Y<br>C      | ilter by:<br>/ear rang<br>Dutcome :<br>Bias:              | e:     | t      | D           |              |             |
| a2007<br>b2001<br>c2008      | F<br>۲<br>(      | ilter by: —<br>/ear rang<br>Dutcome :<br>Bias:            | e:     |        |             |              |             |
| a2007<br>b2001<br>c2008      | -F<br>Y<br>C     | ilter by:—<br>/ear rang<br>Dutcome<br>Bias:               | e:     | to     |             |              |             |
| a2007<br>b2001<br>c2008      | F<br>Y<br>(      | ilter by:—<br>Year rang<br>Dutcome '<br>Bias:             | e:     |        |             |              |             |
| a2007<br>b2001<br>c2008      | -F<br>Y<br>C     | ilter by:—<br>Year rang<br>Dutcome<br>Bias:               | e:     | to     |             |              |             |
| a2007                        | F<br>Y<br>C      | ilter by:—<br>'ear rang<br>Dutcome '<br>Bias:             | e:     |        |             |              |             |
| a2007<br>b2001<br>c2008      | F<br>Y<br>C<br>E | ilter by:<br>/ear rang<br>Dutcome<br>Bias:<br>Bias:       | e:     | ommand | or Shift to | ) select mul | tiple item: |
| a2007<br>b2001<br>c2008      | F<br>Y<br>C<br>E | ilter by:<br>'ear rang<br>Dutcome<br>Bias:<br>b: hold dov | e:     | ommand | or Shift to | ) select mul | tiple item: |

## **Appraise studies**

| Tables   |                                 |   |                |                       |
|--|---------------------------------|---|----------------|-----------------------|
| Characteristics of studies   |                                 |   |                |                       |
| Characteristics of included s     A a2007     B Risk of bias table     a2007     A a2007 | tudies                          |   |                |                       |
| Methods  |                                 |   |                |                       |
| Participants   |                                 |   |                |                       |
| Interventions  |                                 |   | Authors'       |                       |
| Outcomes   | Bias                            |   | judgement      | Support for judgement |
| Notes  | otes Random sequence generation |   |                |                       |
|  | (selection                      | on bias)                                  |                |                       |
|  | Allocatio<br>bias)              | on concealment (selection                 | Unclear risk 💌 |                       |
|  | Blinding<br>(perforr            | of participants and personnel nance bias) | Unclear risk 💌 |                       |
|  | Blinding<br>(detecti            | of outcome assessment on bias)            | Unclear risk 💌 |                       |
|  | Incompl<br>bias)                | ete outcome data (attrition               | Unclear risk 💌 |                       |
|  | Selectiv                        | e reporting (reporting bias)              | Unclear risk 💌 |                       |
|  | Other b                         | ias                                       | Unclear risk 🔻 |                       |

#### **Data input**

#### Choose studies you want to use

| 5 Review Manager 5                                    |  |              |              |         |             |                   |                 |
|---|--|--------------|--------------|---------|-------------|-------------------|-----------------|
| <u>File Edit Format View Tools Table Windo</u>        | w <u>H</u> elp   |              |              |         |             |                   |                 |
|   |  | X2           |              | Ω 🖉     | ]           |                   |                 |
| <b>G</b> [BJL1.RM4] aspirin for miocardial infarction |  |              |              |         |             |                   | °⊏″⊠            |
| 🖹 🕑 🔛 1+2 🟦 🐺 🖑 🖬 🛶 🛔                                 | Text of Review 1.1 Mortality                             |              |              |         |             |                   |                 |
| 👩 Intervention review 😈                               | Comparison: 1 aspirin vs placebo, Outcome: 1.1 Mortality |              |              |         |             | • <b>4 1</b> . (  | * 🖬 🖶 ? 🔲       |
| E Review information                                  | Study or Subgroup  | aspirin      | placebo      | Woight  | Odds R      | Odds              | Ratio           |
| ► IN Main text  |  | Events Total | Events Total | **eigin | M-H, Fixed, | M-H, Fixer        | d, 95% Cl       |
| Tables  | MRC-1 1974   |              |              | 0       | Not e       |                   |                 |
| Characteristics of studies                            | MRC-2 1979   |              |              | 0       | Note        | 1                 |                 |
| Characteristics of studies                            | GASP 1979  | 0 0          | 0            | 0       | Not e       |                   |                 |
|   | PARIS 1980   | 0 0          | 0            | 0       | Not e       |                   |                 |
| AMIS 1980   | AMIS 1980  | 0 0          | 0            | 0       | Not e       |                   |                 |
| ← 🕅 CDP 1976  | ✓ ISIS-2 1988  | 0 0          | 0            | 0       | Not e       |                   |                 |
| GASP 1979   | Total (05% CD  | ,            |              | 0       | Note        |                   |                 |
| • 🕅 ISIS-2 1988                                       | Total events   | 0            | 0            | 0       | NOLE        |                   |                 |
| • MRC-1 1974  | Heterogeneity: Not applicable                            |              |              |         |             |                   |                 |
| ← 🐼 MRC-2 1979  | Test for overall effect: Not applicable                  |              |              |         |             | 0.1 0.2 0.5 1     | 2 5 10          |
| 🔶 🐼 PARIS 1980  |  |              |              |         |             | Favours treatment | Favours control |
| — 🛄 Characteristics of excluded studi                 |  |              |              |         |             |                   |                 |
| — 🛄 Characteristics of studies awaitir                |  |              |              |         |             |                   |                 |
| Characteristics of ongoing studie                     |  |              |              |         |             |                   |                 |
| — 🛄 Summary of findings tables                        |  |              |              |         |             |                   |                 |
| Additional tables                                     |  |              |              |         |             |                   |                 |
| 👇 🕼 Studies and references                            |  |              |              |         |             |                   |                 |
| 🗠 🐼 References to studies                             |  |              |              |         |             |                   |                 |
| ∽ 1 Other references                                  |  |              |              |         |             |                   |                 |
|   |  |              |              |         |             |                   |                 |
| - de 1 achirin ve nlareho                             |  |              |              |         |             |                   |                 |
| • * 1 1 Mortality                                     |  |              |              |         |             |                   |                 |
| - Z- I.I workanty                                     |  |              |              |         |             |                   |                 |
| Courses of ourset                                     |  |              |              |         |             |                   |                 |
| Sources of support                                    |  |              |              |         |             |                   |                 |
| → Feedback  |  |              |              |         |             |                   |                 |
| - E Appendices  |  |              |              |         |             |                   |                 |
|   |  |              |              |         |             |                   |                 |
|   |  |              |              |         |             |                   |                 |
|   |  |              |              |         |             |                   |                 |
|   |  |              |              |         |             |                   |                 |
|   |  |              |              |         |             | •                 | •               |
|   | Eootnote:  |              |              |         |             | $\square$         |                 |
|   | ,  |              |              |         |             |                   |                 |
|   |  |              |              |         |             |                   |                 |

#### **Categorical data Example**

| atudiaa     |          | ASprin   | placebo  |          |  |
|-------------|----------|----------|----------|----------|--|
| studies     | death(n) | total(N) | death(n) | total(N) |  |
| MRC-1 1974  | 49       | 615      | 67       | 624      |  |
| CDP 1976    | 44       | 758      | 64       | 771      |  |
| MRC-2 1979  | 102      | 832      | 126      | 850      |  |
| GASP 1979   | 32       | 317      | 38       | 309      |  |
| PARIS 1980  | 85       | 810      | 52       | 406      |  |
| AMIS 1980   | 246      | 2267     | 219      | 2257     |  |
| ISIS-2 1988 | 1570     | 8587     | 1720     | 8600     |  |

#### **Data input**

| 5 Review Manager 5  |   |                            |  |  |  |  |  |  |  |
|---|---|----------------------------|--|--|--|--|--|--|--|
| <u>F</u> ile <u>E</u> dit F <u>o</u> rmat <u>V</u> iew <u>T</u> ools T <u>a</u> ble <u>W</u> indow <u>H</u> elp |   |                            |  |  |  |  |  |  |  |
| D <mark>≊</mark> ∎ ↓ b ⊂ <b>R</b> ∎@ ♥♥♥ ► <b>B</b> iuxx2 HH## <b>N</b> %Ω ■                                    |   |                            |  |  |  |  |  |  |  |
| <b>[6]</b> [BJL1.RM4] aspirin for miocardial infarction   |   | r ل 🗵                      |  |  |  |  |  |  |  |
| 🕒 🖻 🕰 🔐 1+2 🏦 🏶 🛷 🖬 🖵 🚔 🗸   | Text of Review X 1.1 Mortality  |                            |  |  |  |  |  |  |  |
| 👩 Intervention review 🕝   | Comparison: 1 aspirin vs placebo, Outcome: 1.1 Mortality  |                            |  |  |  |  |  |  |  |
| — 🗈 Title   |   |                            |  |  |  |  |  |  |  |
| ► 🖹 Review information  | Study or Subgroup   | aspirin placebo Odds Ratio |  |  |  |  |  |  |  |
| 🗢 🗐 Main text   | MRC-1 1974  | 49 615 67 6                |  |  |  |  |  |  |  |
| 🕈 🖽 Tables  | CDP 1976  | 44 758 64 7                |  |  |  |  |  |  |  |
| 👇 🎹 Characteristics of studies  | MRC-2 1979  |                            |  |  |  |  |  |  |  |
| 🕈 🔲 Characteristics of included stu   | V GASP 1979   |                            |  |  |  |  |  |  |  |
| 🗕 🗠 🎆 AMIS 1980   | AMIS 1980   |                            |  |  |  |  |  |  |  |
| 🗕 🗠 🕅 CDP 1976 📃  | ✓ ISIS-2 1988   | 1570 8587 1720 88          |  |  |  |  |  |  |  |
| 🗢 🕅 GASP 1979   |   |                            |  |  |  |  |  |  |  |
| 🕨 🗠 🎆 ISIS-2 1988   | Total (95% CI)  | 14186 138                  |  |  |  |  |  |  |  |
| 🔶 🏹 MRC-1 1974  | Total events  | 2128 2286                  |  |  |  |  |  |  |  |
| 🔶 🎆 MRC-2 1979  | Heterogeneity. Chine 9.95, at = 6 (P = 0.13), $P = 40\%$<br>Test for overall effect: $7 = 3.29$ (P = 0.001) | 0.1 0.5 1 2 510            |  |  |  |  |  |  |  |
| - 🕅 PARIS 1980  |   | s treatment Favours co     |  |  |  |  |  |  |  |
| — 🖽 Characteristics of excluded stu   |   |                            |  |  |  |  |  |  |  |
| — 🛄 Characteristics of studies awa  |   |                            |  |  |  |  |  |  |  |
| Characteristics of ongoing stu  |   |                            |  |  |  |  |  |  |  |
| — 🛄 Summary of findings tables  |   |                            |  |  |  |  |  |  |  |
| 🗌 🔲 Additional tables   |   |                            |  |  |  |  |  |  |  |
| 🕶 🕼 Studies and references  |   |                            |  |  |  |  |  |  |  |
| 📍 🚽 Data and analyses   |   |                            |  |  |  |  |  |  |  |
| 🕈 🕂 1 aspirin vs placebo  |   |                            |  |  |  |  |  |  |  |
| 🛉 🛧 🚧 1.1 Mortality   | Footpate  |                            |  |  |  |  |  |  |  |
|   |   |                            |  |  |  |  |  |  |  |
|   |   |                            |  |  |  |  |  |  |  |

#### outcome



#### forest plot

| 5 Review Manager 5  |                  |   |            |          |             |           |                   |                   |   |       |
|---|------------------|---|------------|----------|-------------|-----------|-------------------|-------------------|---|-------|
| <u>F</u> ile <u>E</u> dit F <u>o</u> rmat <u>V</u> iew <u>T</u> ools T <u>a</u> ble <u>W</u> indow <u>H</u> elp |                  |   |            |          |             |           |                   |                   |   |       |
| ∭ <mark>````````````````````````````````````</mark>   |                  |   |            |          |             |           |                   |                   |   |       |
| 👩 [BJL 1.RM4] aspirin for miocardial infarction   |                  |   |            |          |             |           |                   |                   |   |       |
| 💽 💽 🗟 📴 ы 🕼 🖬 🕞 🗸 👔 Text of Review 🕱 1.1 Mortality  |                  |   |            |          |             |           |                   |                   |   |       |
| 👩 Intervention review 🕞   | Comp             | arison: 1 aspiri  | n vs pla   | cebo. Ou | tcome:      | 1.1 Morta | ality             | F                 | -====================================== | 8 ? 🔳 |
| — 🗈 Title   |                  |   |            |          |             |           |                   |                   |   |       |
| 🕶 🖹 Review information  | 📑 Forest plot    |   |            |          |             |           |                   |                   | X                                       | atio  |
| 🗢 🖺 Main text   |                  |   |            | -        | -           |           |                   |                   | 1                                       |       |
| ዮ 🥅 Tables  | Study or Subara  | aspiri<br>un Events   | n<br>Total | place    | b0<br>Total | Moight    | Odds Ratio        | Odds<br>M H Eive  | Ratio                                   |       |
| 👇 🎹 Characteristics of studies  | MRC-1 1974       | 49  | 615        | 67       | 624         | 3.2%      | 0.72 [0.49, 1.06] | INI-11, 1 IAG     |   |       |
| 👇 🖽 Characteristics of inclu  | CDP 1976         | 44  | 758        | 64       | 771         | 3.1%      | 0.68 [0.46, 1.01] |                   |   |       |
| 🔶 🏹 AMIS 1980   | MRC-21979        | 102   | 832        | 126      | 850         | 5.7%      | 0.80 [0.61, 1.06] |                   |   |       |
| 🔶 🀼 CDP 1976  | PARIS 1980       | 32<br>85  | 317<br>810 | 50<br>52 | 309<br>406  | 3.2%      | 0.80 [0.49, 1.32] |                   | -                                       | ſ II  |
| 🗢 🕅 GASP 1979   | AMIS 1980        | 246   | 2267       | 219      | 2257        | 10.2%     | 1.13 [0.93, 1.37] | -                 | -                                       |       |
| - 🐼 ISIS-2 1988   | ISIS-2 1988      | 1570  | 8587       | 1720     | 8600        | 72.9%     | 0.89 [0.83, 0.97] | _                 |   |       |
| 🗢 🐼 MRC-1 1974  | Total (95% CI)   |   | 14186      |          | 13817       | 100.0%    | 0.90 [0.84, 0.96] | •                 |   |       |
| 🗲 🐻 MRC-2 1979  | Total events     | 2128  |            | 2286     |             |           |                   |                   |   | 2 510 |
| ← 🕅 PARIS 1980  | Heterogeneity: C | Heterogeneity: Chi <sup>2</sup> = 9.95, df = 6 (P = 0.13); i <sup>2</sup> = 40%<br>0.1 0.2 0.5 1 2 5 10 |            |          |             |           | Favours co        |                   |   |       |
| — Enaracteristics of exclu  |                  | anett. Ζ = 3.29 (F  | - 0.00     | <u> </u> |             |           |                   | Favours treatment | Favours control                         |       |
| — 🛄 Characteristics of stud   |                  |   |            |          |             |           |                   |                   |   |       |
| 📃 💷 Characteristics of ongo   |                  |   |            |          |             |           |                   | Add as Figure     | Cancel                                  |       |
| — 🛄 Summary of findings tables  | 5                |   |            |          |             |           |                   |                   |   | -     |
| 🔲 Additional tables   |                  |   |            |          |             |           |                   |                   |   |       |
| 👇 🕼 Studies and references  |                  |   |            |          |             |           |                   |                   |   |       |
| 👇 君 Data and analyses   |                  |   |            |          |             |           |                   |                   |   |       |
| 🛉 🕼 1 aspirin vs placebo  |                  |   |            |          | 1           |           |                   |                   |   |       |
| + 1.1 Mortality   |                  |   |            | 1        |             |           |                   |                   |   |       |
|   | ▼ Eootno         | ote:  |            |          |             |           |                   |                   |   |       |
|   |                  |   |            |          |             |           |                   |                   |   |       |
|   |                  |   |            |          |             |           |                   |                   |   |       |

#### results

| 5 Review Manager 5                         |                |  | _ @ <mark>_</mark> X |
|--|----------------|--|----------------------|
| <u>File Edit Format View Tools Table V</u> | <u>M</u> indow | / Help   |                      |
|  | <b>n</b> (1    | C C C C C C C C C C C C C C C C C C C  |                      |
| 👩 [BJL1.RM4] aspirin for miocardial infarc | tion 📓         |  | ᄚᅜᢂ                  |
| 💽 🖻 🖪 😭 1+2 🏦 🐺 🛷 🕞 📇 .                    |                | Text of Review 🛛 🔀 1.1 Mortality 🔀 Figure 1 (Analysis 1.1)   |                      |
| 👩 Intervention review 🕝                    |                | 😲 This figure is updated dynamically when the data change. 🛛 📳 👔 🖉 🕞   | 3 ? 🔲                |
| — 🖹 Title                                  |                |  |                      |
| <ul> <li>Review information</li> </ul>     |                | aspirin placebo Odds Ratio Odds Ratio Odds Ratio<br>Study or Subgroup Events Total Events Total Weight M-H, Fixed, 95% Cl M-H, Fixed, 95% Cl |                      |
| - Windin text                              |                | MRC-1 1974 49 615 67 624 3.2% 0.72 [0.49, 1.06]  |                      |
| Characteristics of studies                 |                | MRC-21979 102 832 126 850 5.7% 0.80 [0.61, 1.06]   |                      |
| Characteristics of included stu            |                | GASP 1979 32 317 38 309 1.8% 0.80 [0.49, 1.32]   | _                    |
| - 🕅 AMIS 1980                              |                | AMIS 1980 246 2267 219 2257 10.2% 1.13 [0.93, 1.13]  |                      |
| 🗠 🐼 CDP 1976                               |                | ISIS-2 1988 1570 8587 1720 8600 72.9% 0.89 [0.83, 0.97]  |                      |
| 🗠 🕅 GASP 1979                              |                | Total (95% Cl) 14186 13817 100.0% 0.90 [0.84, 0.96]  |                      |
| • 🐼 ISIS-2 1988                            |                | Total events 2128 2286   | +                    |
| MRC-1 1974                                 |                | Test for overall effect 7 = 3.29 (P = 0.001)         0.1 0.2         0.5 1         2   | 5 11-                |
|  |                |  |                      |
| Characteristics of excluded stu            |                |  |                      |
| — 🛄 Characteristics of studies awa         |                |  |                      |
| 🗌 🔲 Characteristics of ongoing stu         |                |  |                      |
| – 🛄 Summary of findings tables             |                |  |                      |
| Additional tables                          |                |  |                      |
| • W Studies and references                 |                |  |                      |
| Y → Data and analyses                      |                | Caption: Figure 1 (Analysis 1.1)   |                      |
| • * 1.1 Mortality                          |                | Forest plot of comparison: 1 aspirin vs placebo, outcome: 1.1 Mortality.   |                      |
|  | -              |  |                      |
|  | 8              |  |                      |

## **Funnel plot**



## result for Meta analysis

Effect size & 95%CI 0.90(0.84-0.96)
 Fixed effect model or random effect model
 test for heterogeneity, χ2, P, (χ2=9.55, P=0.13, 12=40%)

**\Box** Test for overall effect, Z and P (Z=3.29, P=0.001)

## **Questions For you**

- □ 1.How many types of studies can be pooled?
- □ 2. What does mean by comparison in Revman?
- □ 3. What does mean by outcome?
- **4**.How many types of data can be ?
- **5**.what results do you get from Revman?
- □ 6. can you assess the quality of studies in Revman?

| 5 Review Manager 5                       |     |                             | <b>—</b> C |           | nti        | ht      |      |                           | dai      |                    |                                       | }          |
|--|-----|-----------------------------|------------|-----------|------------|---------|------|---------------------------|----------|--------------------|---------------------------------------|------------|
| <u>File Edit Format View Tools Table</u> | v v | <u>V</u> indow <u>H</u> elp |            |           |            |         |      |                           |          |                    |                                       |            |
|  |     |                             | OK∕ ₩SC    | <u>)</u>  |            |         | B ì  | <u>u</u> × <sup>2</sup> > |          |                    |                                       |            |
| 👩 continuous data for [health problem]   |     |                             |            |           |            |         |      |                           |          |                    | ° ⊏ٹ [                                | X          |
| 🔁 🖻 🗟 📄 1+2 🏦 🐺 🛷 🗸 👔                    | Tex | kt of Review 🛛 🗙 1.1        | l continuo | us        |            |         |      |                           |          |                    |                                       |            |
| Intervention review                      | Co  | mparison: 1 continuou       | ıs data. O | .tcome: ' | 1.1 contir | nuous   |      |                           |          |                    |                                       | 1          |
| — 🗈 Title                                |     | •                           | ,          |           |            |         |      |                           |          |                    |                                       |            |
| 🗢 🗟 Protocol information                 |     | Study or Subgroup A         | Ex         | periment  | al         | Control |      |                           | Weight - | Mean Difference 🛔  | Mean Difference                       |            |
| ► 🗈 Main tevt                            |     |                             | Mean       | SD        | Total      | Mean    | SD   | Total                     | 0.40     | IV, Fixed, 95% CI  | IV, Fixed, 95% CI                     |            |
|  |     | SU1                         | 2.26       | 0.32      | 26         | 2.33    | 0.33 | 42                        | 9.1%     | -0.07 [-0.23, 0.1  |                                       |            |
|  |     | SUZ                         | 2.39       | 0.31      | 55         | 2.49    | 0.32 | 40                        | 13.8%    | -0.10 [-0.23, 0.1  |                                       |            |
| 📍 🕼 Studies and references               |     | SU3                         | 2.0        | 0.3       | 40         | 2.07    | 0.30 | 50                        | 10.7%    | -0.17 [-0.30, -0.1 |                                       |            |
| 🗢 🐼 References to studies                |     | 504<br>c05                  | 2.04       | 0.20      | 40         | 2.9     | 0.40 | 45                        | 10.7%    | -0.20[-0.41,-0.    |                                       |            |
| 🗢 🕼 Other references                     |     | 505<br>S06                  | 2.01       | 0.00      | 43<br>52   | 3.27    | 0.30 | 55                        | 9.1%     | -0.32 [-0.48 -0.1  |                                       |            |
| 👇 📲 Data and analyses                    |     | s07                         | 3.15       | 0.39      | 46         | 3.48    | 0.48 | 42                        | 6.8%     | -0.33 [-0.51, -0.1 |                                       |            |
| 🗣 🕼 1 continuous data                    |     | s08                         | 3.47       | 0.46      | 45         | 3.73    | 0.54 | 51                        | 5.7%     | -0.26 [-0.46, -0.1 |                                       |            |
|  | V   | s09                         | 3.63       | 0.38      | 45         | 3.81    | 0.4  | 45                        | 8.8%     | -0.18 [-0.34, -0.1 |                                       |            |
|  |     | s10                         | 3.81       | 0.41      | 42         | 4.16    | 0.42 | 45                        | 7.5%     | -0.35 [-0.52, -0.  |                                       |            |
| Figures                                  | ~   | s11                         | 3.99       | 0.56      | 44         | 4.18    | 0.41 | 25                        | 4.3%     | -0.19 [-0.42, 0.1  |                                       |            |
| 🗢 🐯 Sources of support                   |     |                             |            |           |            |         |      |                           |          |                    |                                       |            |
| — 😲 Feedback                             |     | Total (95% Cl)              |            |           | 491        |         |      | 490                       | 100.0%   | -0.20 [-0.25, -0.1 |                                       |            |
| 🗏 🗎 Appendices                           |     | Heterogeneity: Chi²         |            |           |            |         |      |                           |          |                    |                                       |            |
|  |     | Test for overall effe       |            |           |            |         |      |                           |          |                    | -100 0 50100<br>perimental Eavours co |            |
|  |     |                             |            |           |            |         |      |                           |          |                    |                                       |            |
|  |     |                             |            |           |            |         |      |                           |          |                    |                                       |            |
|  |     |                             |            |           |            |         |      |                           |          |                    |                                       |            |
|  |     |                             |            |           |            |         |      |                           |          |                    |                                       |            |
|  |     |                             |            |           |            |         |      |                           |          | 1000               |                                       |            |
|  |     |                             |            |           |            |         |      |                           |          |                    |                                       |            |
|  |     |                             |            |           |            |         |      |                           |          |                    |                                       |            |
|  | •   |                             |            |           |            | 111     |      |                           |          |                    |                                       |            |
|  | Eoc | otnote:                     |            |           |            |         |      |                           |          |                    |                                       |            |
|  |     |                             |            |           |            |         |      |                           |          |                    |                                       | <u>'</u> ] |

#### **Continuous data**

| 5 Review Manager 5   |   |  |                          |   |                                       |
|--|---|--|--------------------------|---|---------------------------------------|
| <u>File E</u> dit F <u>o</u> rmat <u>V</u> iew <u>T</u> ools T <u>a</u> bl | le <u>W</u> indow <u>H</u> elp  |  |                          |   |                                       |
| ┣┏∎ ➡♣ ⊒ ♦◄  |   | 🕸 😵 🏠 Nori                                   | mal 💌 B                  | <i>i</i> <u>u</u> x <sup>2</sup> x <sub>2</sub> <i>∎</i> ⋮≡ | 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 |
| 👩 continuous data for [health problem                                      | n]  |  |                          |   | ㅎ 다 🛛                                 |
| 🔁 🔁 🔛 1+2 🏦 🐺 🛷 🗸  | Text of Review 🗶 1.1 c  | continuous 🛛 🗙 F                             | igure 1 (Analysis 1      | .1)   |                                       |
| Intervention review  | This figure is updated d  | tynamically when t                           | he data change.          |   |                                       |
| — 🗈 Title  |   |  |                          |   |                                       |
| 🗠 🗟 Protocol information   |   | Experimental                                 | Control                  | Mean Difference   | Mean Difference 🔷                     |
| 🗢 🗎 Main text  | Study or Subgroup M   | <u>lean SD Total</u>                         | Mean SD Total            | <u>  Weight IV, Fixed, 95% Cl</u>                           | IV, Fixed, 95% Cl                     |
| 🗣 🎞 Tables   | s02   | 2.39 0.31 55                                 | 2.33 0.33 42             | . 9.1% -0.07[-0.23, 0.09]<br>) 13.8% -0.10[-0.23, 0.03]     | <b>_</b>                              |
| - 🕼 Studies and references   | s03   | 2.5 0.3 46                                   | 2.67 0.35 50             | ) 13.5% -0.17 [-0.30, -0.04]                                | _ <b>-</b>                            |
| 🔶 🌆 References to studies  | s04   | 2.64 0.26 45                                 | 2.9 0.45 50              | ) 10.7% -0.26 [-0.41, -0.11]                                |                                       |
| • 🕅 Other references   | SU5<br>c06  | 2.81 U.35 45<br>2.95 0.46 52                 | 2.93 0.36 45             | ) 10.6% -0.12[-0.27,0.03]<br>5 9.1% -0.32[-0.480.16]        |                                       |
| • = = Data and analyses  | s07   | 3.15 0.39 46                                 | 3.48 0.48 42             | 8 6.8% -0.33 [-0.51, -0.15]                                 |                                       |
|  | s08   | 3.47 0.46 45                                 | 3.73 0.54 51             | 5.7% -0.26 [-0.46, -0.06]                                   | [ ] ] ] ] ] ] ] ] ] ] ] ] ] ] ] ]     |
|  | s09   | 3.63 0.38 45                                 | 3.81 0.4 45              | 5 8.8% -0.18 [-0.34, -0.02]                                 |                                       |
| 1.1 continuous   | s11   | 3.81 0.41 42                                 | 4.10 0.42 40             | 5 7.5% -0.35[-0.52,-0.18]<br>5 4.3% -0.19[-0.42.0.04]       | III                                   |
| • 🔤 Figures  |   | 0.000 0.000 11                               |                          |   |                                       |
| 🗢 😽 Sources of support   | Total (95% CI)  | 491  | 490                      | 0 100.0% -0.20 [-0.25, -0.15]                               |                                       |
| – 😲 Feedback   | Heterogeneity: Chi <sup>2</sup> = 14.<br>Test for overall effect: 7 = | .27, df = 10 (P = 0.1<br>- 9 21 /P < 0 00001 | 6); I <sup>2</sup> = 30% |   | -0.5 -0.25 0 0.25 0.4                 |
| 🗕 🗏 🗎 Appendices   |   | - 1 21 11 - 5 11 10 10 11                    | 1                        |   |                                       |
|  |   |  |                          |   |                                       |
|  |   |  |                          |   |                                       |
|  |   |  |                          |   |                                       |
|  |   |  |                          |   |                                       |
|  |   |  |                          |   |                                       |
|  |   |  |                          |   |                                       |
|  | Caption: Figure 1 (Analysi  | is 1.1)                                      |                          |   |                                       |
|  | Forest plot of comparis   | on: 1 continuous                             | data, outcome:           | 1.1 continuous.   |                                       |
|  |   |  | -                        |   |                                       |
|  |   |  |                          |   |                                       |
|  |   |  |                          |   |                                       |

#### **Continuous data**



## **Questions ?**

Time for PracticeQuestions any time!

